Non-small Cell Lung Cancer
Conditions
Keywords
EGFR mutation, EGFR-TKI, Chemotherapy
Brief summary
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib have proved effective in second or third line therapy for advanced non-small cell lung cancer(NSCLC).It is well tolerated without the side effects usually associated with chemotherapy. The mutations in EGFR exons 19 or 21 have been reported to be associated with efficacy of EGFR TKIs.Based on the encouraging preliminary results from the Spanish lung cancer group' prospective study reported that the efficacy of Tarceva as first line treatment for metastatic NSCLC patients with EGFR mutation would delay disease progression,prolong overall survival and be well tolerated, medium Progression-free survival(PFS) was around 12 months and OS reach 24 months，our study is designed to compare PFS between the patients with mutant EGFR treated by gemcitabine/carboplatin and those by erlotinib in the first-line setting. We assumed 11 months of PFS on Tarceva arm versus 6 months on chemotherapy arm with a=0.025(alpha-spend for an interim analysis), 80% power and 12 months enrolment period, 12 months FU duration to calculate the sample size. The sample size is 69 pairs. Considering about 10% drop-out rate, the final sample size is 152 patients.So, chemo-naive staged IIIb/IV patients with EGFR mutations in exon 19 or 21 will be enrolled into this open-label, randomized,multicenter phase III study.
Detailed description
Primary Outcome Measures: Progression-free survival(PFS) Secondary Outcome Measures: Overall response rate(ORR), overall survival(OS), quality of life(QOL),etc. Estimated Enrollment: 160 Study Start Date: August 2008 Estimated Study Completion Date: August 2010 The patients will be randomized into the following two arms: Arm A: erlotinib 150mg once per day up to disease progression or intolerable toxicity. Arm B: Gemcitabine (1000mg/m2, IV,d1 and d8) plus Carboplatin (AUC=5, IV d1) repeated every 3 weeks up to 4 cycles.
Interventions
DRUGerlotinib
erlotinib 150 mg oral, once a day
gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
Sponsors
Sun Yat-sen University
Shanghai Chest Hospital
RenJi Hospital
Guangdong Provincial People's Hospital
Peking Union Medical College Hospital
Tongji University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Stage IIIB (cytological confirmed with malignant pleural effusion or pericardial effusion) or histopathological or cytological confirmed stage IV NSCLC or relapsed after complete resection . 2. EGFR exon19 deletions or exon 21 L858R mutation by the DNA direct PCR sequencing using fresh tumor sample or paraffin embed tumor sample. 3. Measurable lesions as defined by RECIST criteria . 4. Palliative radiotherapy allowed if it was finished 3 weeks after the first drug administration, but the target lesions should not be included in the radiotherapy field. 5. Patients with operation are allowed if the operation is 4 weeks before the first drug administration 6. Men or women of at least 18 years of age. 7. ECOG Performance status of 0 to 2. 8. Estimated life expectancy of at least 12 weeks. 9. Patient compliance and geographic proximity that allow adequate follow-up. 10. Adequate organ function tested 7 days before the first drug administration: hemoglobin ≥9 g/dL,absolute neutrophil count (ANC) ≥1.5\*109/L, platelets ≥100 \*109/L,bilirubin ≤1.5ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 upper limited number(ULN) (AP, AST, ALT ≤5ULN is acceptable if liver has tumor involvement).INR≤1.5, APTT in the normal range( 1.2DLN-1.2ULN),creatinine ≤1.5ULN. 11. Informed consent from the patient.
Exclusion criteria
1. Have received systemic anti-cancer therapy, including Cytotoxic drugs, targeted therapy, experimental treatment, adjuvant or neo-adjuvant therapy(except the disease relapse 6 months after the final drug) 2. Wild type EGFR. 3. Uncontrolled pericardial or pleural effusions prior to study entry. 4. History of cardiovascular disease: Congestive Heart Failure \> grade II in NYHA. Unstable angina patients (have angina symptoms in rest) or a new occurrence of angina (began in the last 3 months) or myocardial infarction happens in the last 6 months 5. Brain metastasis (controlled brain metastasis and steroid free need is excluded). 6. HIV infection 7. Active infection, \>grade 2 in Common Terminology Criteria for Adverse Events(CTCAE) version 3. 8. A history of operation or serious traumatic 3 weeks before the first drug administration 9. Patient with other malignant tumor except NSCLC 5 years previous to study entry. Excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial tumor \[including Ta and Tis\] 10. Mixed with small cell lung cancer 11. Unable to swallow drugs. 12. Malabsorption 13. Pregnant or child breast feeding women 14. Childbearing patients will not use a reliable method of contraception before the study entry, during process of the study and within 30 days after discontinuation of the study. Reliable contraceptive methods will be determined by principal investigator or a designated officer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| OS | 24 months |
| ORR | 24 months |
| Time to Progression | 24 months |
| lung cancer symptoms and health-related quality of life (HRQoL) | 24 months |
| explore the biological markers (tumor tissue) | 24 months |
Countries
China
Outcome results
None listed